NewslettersCell Therapy News DNAJB1-PRKACA Fusion Neoantigens Elicit Rare Endogenous T Cell Responses That Potentiate Cell Therapy for Fibrolamellar Carcinoma By lbeveridge - March 25, 2024 0 Scientists defined endogenous CD8 T cell responses to a conserved DNAJB1-PRKACA gene fusion in fibrolamellar carcinoma patients and evaluate fusion-specific T cell receptors for use in cellular immunotherapies. [Cell Reports Medicine] Full ArticleGraphical Abstract